Kopin Q2: Revenue down 31%, margins crushed; $24.8M litigation hangover, $15M deal pending

Kopin Corporation (NASDAQ: KOPN) - what's happening inside the company

Snapshot (as of June 28, 2025)
- Cash and cash equivalents: $24,369,310
- Restricted cash: $1,050,000
- Marketable securities (fair value): $2,417,877
- Cash + restricted + marketable securities: $27.8M (total per disclosures)
- Total assets: $61,184,830 * Total liabilities: $45,144,996 * Stockholders' equity: $16,039,834
- Accounts receivable, net: $9,481,332 * Contract assets: $6,840,887 * Inventory: $6,685,225
- Accrued litigation damages (recorded): $24,800,000

Income statement - key numbers (Q2 2025 vs Q2 2024)
- Total revenue: $8,454,883 vs $12,336,423 (down ~31%)
- Net product revenue: $7,498,436 vs $11,054,030
- Cost of product revenues: $7,071,517 (94% of product sales for Q2 2025 vs 79% prior-year quarter)
- Research & development revenue: $907,907
- R&D expense: $1,945,436 (up slightly YoY)
- Selling, general & administrative: $4,899,313 (down from $7,267,868 YoY)
- Loss from operations: $(5,461,383) (flat YoY operational loss)
- Net loss: $(5,166,633) vs $(5,921,998) prior year quarter
- Basic & diluted net loss per share (Q2): $(0.03); weighted average shares: 166,351,615

Positive aspects (income statement & balance-sheet related)
- SG&A down materially (Q2 SG&A $4.9M vs $7.27M), reflecting lower legal fees and cost control.
- Other income improved: interest and investment gains turned total other income to +$346,750 in Q2 (versus a loss prior-year), helping offset operating losses.
- Net loss narrowed versus prior-year periods (six months loss $8.28M vs $38.47M in prior year six months) largely because last year included accrued litigation damages and one-time legal costs.
- Liquidity improved vs immediate operational burn through sales of marketable securities in H1 2025 (cash from investing activity $17.9M).

Negative aspects (income statement & financial risks)
- Revenues down ~31% YoY in the quarter - demand weakness in defense product lines (thermal weapon sights, pilot helmets) is a clear headwind.
- Gross margins compressed severely: cost of product revenues ~94% of product sales in Q2 (under-absorption of overhead from lower volume). That leaves little room to profit even if SG&A is cut.
- Continued operating losses: Q2 operating loss $(5.46M) and six-month operating loss $(9.37M). Company remains unprofitable.
- Large litigation overhang: $24.8M accrued litigation damages remain on the balance sheet and litigation exposure (possible additional fees, injunction risk) is unresolved.
- Material weaknesses in internal controls cited - disclosure, IT access, revenue cycle and documentation deficiencies increase audit/operational risk.
- Going-concern risk: management states substantial doubt about ability to continue as a going concern for 12 months without additional financing or strategic transactions.

Operational & corporate developments
- Revenue mix: ~97% of Q2 sales are U.S. customers; Defense remains the largest application (Q2 defense revenue $6.22M).
- R&D: internal R&D spending increased (internal R&D $1.48M Q2) while funded R&D decreased as some programs moved to production.
- Equity and share activity: outstanding common shares (Aug 12, 2025 reported): 162,805,852; weighted average diluted shares in Q2 ~166.35M - dilution potential from warrants/restricted stock and recent financings.
- Stock-based compensation continues: $747,717 in Q2 and $1.52M YTD; unrecognized restricted stock expense ~$7.5M over ~2 years.
- Post-period strategic financing (August 8, 2025): announced conditional agreements with Theon International Plc for aggregate $15M (49% buy of Kopin Europe + $7M Series A preferred). This is conditional and subject to closing and approvals but would materially bolster liquidity if completed.

What to watch next
- Progress and closing of the Theon strategic investment (timing and terms, conversion mechanics, dilution).
- Litigation outcomes (BlueRadios) - potential final judgment, injunction risk and any additional accruals or reversals.
- Revenue trends and margin recovery - whether defense demand and production volume improve to restore gross margin and absorb overhead.
- Ability to remediate material weaknesses - fixes to IT/general controls and revenue accounting to restore investor confidence and reduce audit risk.
- Cash runway assuming current operating cash use (~$7.6M cash used in operations in H1 2025) and no significant new financing.

Bottom line: Kopin (NASDAQ: KOPN) is managing cost reductions and has improved non-operating income, but revenue declines and very weak gross margins keep it loss-making and dependent on external financing or strategic partnerships. The $24.8M litigation accrual and disclosed material weaknesses elevate risk; the announced Theon investment is the clearest near-term positive path to shore up liquidity but remains conditional.